gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NXLHealthcareElectromedical Equipment

Nexalin Technology, Inc. Common Stock (NXL)

$1.56+1.30%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.56▼ 96.23% in range
Nov 4, 2025Low $1.50 · High $225.00Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Nexalin Technology closed at $1.56 on Nov 4, up 1.30%, 99.3% below its 52-week closing high. Volume of 17.3K shares was 0.23× its 20-day average (below normal).

Split-adjusted performance: -65.3% over one month, -85.1% over six months, -96.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $12.16K, down 82.8% from a year earlier, with a net margin of -18412.7%.

Short interest was 4.5K shares at the Oct 15 settlement, down 65.7% from the prior report (0.0% of float, 1.0 days to cover).

Market cap$1.6M1.0M shares
Revenue · quarter$12.2K−82.8% YoY
Diluted EPS$-3.30—
P/E · TTM—P/S 7.5×
Net margin-18,412.7%Gross 73.2%
Dividend yieldNone$0.3125 last paid
52-week range1.50 – 225.00−99.3% from high
Volume17.3K0.23× 20-day avg
Volatility · 60d1,001.3%Annualised
Short % of float0.0%1.0 days to cover
Net cash$1.0MCash $1.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.3%1M −65.3%3M −84.6%6M −85.1%YTD −90.7%1Y −96.5%3Y −83.5%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Electromedical Equipment

Percentile among 22 companies (100 = best)

6-month momentum5
Revenue growth0
Net margin0
Value (low P/E)—
Size0

Industry medians: 6-month return −0.9%, revenue growth +13.9%, net margin −44.6%, P/E 23.7×.

Short interest

Details →
Shares short4.5K−65.7% vs prior
Days to cover1.0Settled Oct 15
% of float0.0%
Short vol. 10d34.2%of daily volume

Closest peers by size in Electromedical Equipment

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NXLNexalin Technology$1.56+1.30%−85.1%−82.8%−18412.7%—$1.6M
NUWENuwellis$5.27−10.83%−98.5%+14.1%−245.1%—$2.1MCompare
NDRAENDRA Life Sciences$4.94+1.65%+1.6%———$7.4MCompare
IRIXIridex$0.7151+2.74%−31.2%−7.4%−10.1%—$12.6MCompare
QTIQT Imaging Holdings$2.19+1.39%−69.2%+103.2%−148.9%—$32.1MCompare
STEXStreamex$0.3610−5.00%−64.3%—−9968.5%—$42.0MCompare
POCIPrecision Optics$4.84+3.42%+2.8%+42.0%−1.2%—$53.2MCompare
ECORelectroCore$8.40+16.18%+26.1%+28.0%−32.4%—$75.7MCompare
HYPRHyperfine$0.7503+8.36%−56.6%+44.8%−238.2%—$79.6MCompare

News about Nexalin Technology

All news →
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and InsomniaGlobeNewswire Inc. · Jun 4, 2026▲ PositiveNexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsGlobeNewswire Inc. · Apr 9, 2026▲ Positive

Quick answers

What does Nexalin Technology do?
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S.
What is NXL's market cap?
$1.64M, based on the Nov 4 close of $1.56.
Does Nexalin Technology pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NXL is sold short?
4.5K shares, 0.0% of float, as of Oct 15, 2026.
What sector is NXL in?
Healthcare, in the Electromedical Equipment industry.

About Nexalin Technology

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

HQ: Houston, TX8 employeesListed Sep 16, 2022nexalin.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology